OR WAIT 15 SECS
Scimega Research, a Canadian-based specialty oncology clinical research organization, is pleased to announce that it has been selected by The Quebec - Clinical Research Organization in Cancer (Q-CROC) to successfully oversee the conduct of three of pivotal studies to identify predictive biomarkers in drug-resistant tumors.
Scimega Research, (www.scimega.com) a Canadian-based specialty oncology clinical research organization (CRO), is pleased to announce that it has been selected by The Quebec – Clinical Research Organization in Cancer (Q-CROC) to successfully oversee the conduct of three of pivotal studies to identify predictive biomarkers in drug-resistant tumors.
This comes on the heels of the announcement made this past February 15th by the Minister of Finance and the Economy, Nicolas Marceau and the Minister for Industrial Policy and the Quebec Economic Development Bank, Élaine Zakaïb, of a $10 million investment in the Personalized Medicine Partnership for Cancer (PMPC), a historic initiative of public-private partnership that marks a turning point for the province in the implementation of personalized medicine in cancer. The PMPC will be supported in its deployment by the Q-CROC’s hospital and university network, which currently has members in 15 healthcare establishments and 16 research centers in the province.
“We are delighted to collaborate on these projects. Q-CROC’s vision is perfectly aligned with our mission to support cutting edge oncology clinical research,” commented Dr. Luc Daigneault, Director of Clinical & Scientific Affairs for Scimega. “Personalized medicine represents a paradigm shift for the key stakeholders involved in cancer drug development. Collectively, we all have an important role to play in the fight against cancer and this is an excellent example of a unifying partnership that brings us one step closer to making personalized medicine a reality, and patient-centered treatment, a standard” said Denise Deakin, President & co-founder of Scimega Research Inc.